比较接受新辅助化疗与初始肿瘤细胞减灭术的老年卵巢癌患者的生存:通过机器学习减少偏倚
本研究利用SEER-Medicare数据开发多维合并症指数(MCI),在4723例开发队列和933例验证队列中评估其预测1年死亡率及减少混杂的能力。MCI对1年死亡的区分度(c-index 0.75)优于Charlson合并症指数(c-index 0.59);控制MCI后,新辅助化疗与初始手术的全因死亡风险差异无统计学显著(HR 1.05,95%CI 0.96-1.14)。
要点
- MCI对1年死亡的区分度优于CCI(c-index 0.75 vs 0.59)。
- 控制CCI时NACT死亡风险更高(HR 1.13,95%CI 1.04-1.23)。
- 控制MCI后NACT与手术死亡风险无显著差异(HR 1.05,95%CI 0.96-1.14)。
核心结论
- MCI在预测1年死亡率和减少新辅助化疗与初始手术比较效果分析中基线健康状况差异所致混杂方面优于传统CCI。
研究设计与样本
- 利用SEER-Medicare数据识别2010-2015年诊断的IIIC期和IV期卵巢癌患者,开发队列4723例,验证队列933例。
- 采用偏最小二乘回归(一种监督机器学习算法),通过提取潜伏因子开发MCI,以最优捕捉癌症诊断前一年医疗保险索赔变异和1年死亡率。
- 评估MCI对1年死亡率的区分度和校准度,并与常用CCI比较。
- 评估MCI在新辅助化疗(NACT)与全因死亡关联中减少混杂的能力。
主要发现
- MCI对1年死亡率显示良好区分度(c-index:0.75,95%CI:0.72-0.79),而CCI区分度差(c-index:0.59,95%CI:0.56-0.63)。
- 校准图显示MCI预测与观察的1年死亡风险一致性优于CCI。
- 控制肿瘤特征、人口学因素和CCI后,NACT与初始肿瘤细胞减灭术相比,全因死亡风险更高(HR:1.13,95%CI:1.04-1.23)。
- 控制MCI而非CCI后,NACT与初始手术的全因死亡风险差异不再显著(HR:1.05,95%CI:0.96-1.14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and evaluate a multidimensional comorbidity index (MCI) that identifies ovarian cancer patients at risk of early mortality more accurately than the Charlson Comorbidity Index (CCI) for use in health services research. METHODS: We utilized SEER-Medicare data to identify patients with stage IIIC and IV ovarian cancer, diagnosed in 2010-2015. We employed partial least squares regression, a supervised machine learning algorithm, to develop the MCI by extracting latent factors that optimally captured the variation in health insurance claims made in the year preceding cancer diagnosis, and 1-year mortality. We assessed the discrimination and calibration of the MCI for 1-year mortality and compared its performance to the commonly-used CCI. Finally, we evaluated the MCI's ability to reduce confounding in the association of neoadjuvant chemotherapy (NACT) and all-cause mortality. RESULTS: We included 4723 patients in the development cohort and 933 in the validation cohort. The MCI demonstrated good discrimination for 1-year mortality (c-index: 0.75, 95% CI: 0.72-0.79), while the CCI had poor discrimination (c-index: 0.59, 95% CI: 0.56-0.63). Calibration plots showed better agreement between predicted and observed 1-year mortality risk for the MCI compared with CCI. When comparing all-cause mortality between NACT with primary cytoreductive surgery, NACT was associated with a higher hazard of death (HR: 1.13, 95% CI: 1.04-1.23) after controlling for tumor characteristics, demographic factors, and the CCI. However, when controlling for the MCI instead of the CCI, there was no longer a significant difference (HR: 1.05, 95% CI: 0.96-1.14). CONCLUSIONS: The MCI outperformed the conventional CCI in predicting 1-year mortality, and reducing confounding due to differences in baseline health status in comparative effectiveness analysis of NACT versus primary surgery.
引用
- Huang Y, Rauh-Hain JA, McCoy TH, et al. Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning. Gynecol Oncol. 2024. PMID: 38554626. doi:10.1016/j.ygyno.2024.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。